Yao Luxia, Wang Lei, Zhang Runshuai, Soukas Alexander A, Wu Lianfeng
School of Life Sciences, Westlake University, Hangzhou, Zhejiang, China; Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, Zhejiang, China; Key Laboratory of Growth Regulation and Translational Research of Zhejiang Province, Hangzhou, Zhejiang, China; Research Center for Industries of the Future, Westlake University, Hangzhou, Zhejiang, China; Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, Hangzhou, Zhejiang, China.
School of Life Sciences, Westlake University, Hangzhou, Zhejiang, China; Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, Hangzhou, Zhejiang, China.
Trends Endocrinol Metab. 2025 Apr;36(4):364-372. doi: 10.1016/j.tem.2024.07.017. Epub 2024 Sep 2.
Metformin, an oral antihyperglycemic drug that has been in use for over 60 years, remains a first-line therapy for type 2 diabetes (T2D). Numerous studies have suggested that metformin promotes health benefits beyond T2D management, including weight loss, cancer prevention and treatment, and anti-aging, through several proposed mechanistic targets. Here we discuss the established effects of metformin and the progress made in identifying its direct targets. Additionally, we emphasize the importance of elucidating the structural bases of the drug and its direct targets. Ultimately, this review aims to highlight the current state of knowledge regarding metformin and its related emerging discoveries, while also outlining critical future research directions.
二甲双胍是一种已使用超过60年的口服降糖药，仍然是2型糖尿病（T2D）的一线治疗药物。大量研究表明，二甲双胍通过几个提出的作用机制靶点，在2型糖尿病管理之外还能带来诸多健康益处，包括体重减轻、癌症预防和治疗以及抗衰老。在此，我们讨论二甲双胍已明确的作用以及在确定其直接靶点方面取得的进展。此外，我们强调阐明该药物及其直接靶点的结构基础的重要性。最终，本综述旨在突出关于二甲双胍及其相关新发现的当前知识状态，同时概述未来关键的研究方向。
